Sanofi’s reportedly on the verge of ‘sizable’ job cuts as diabetes business sputters

Damian Garde French drugmaker Sanofi is soon to announce some "sizable" cuts to its payroll, according to Stat, part of new CEO Olivier Brandicourt's plot to engineer ...

Theracos raises $25M to take on Big Pharma in diabetes

Damian Garde Marlborough, MA's Theracos raised $ 25 million to support its work on a safer version of a common treatment for Type 2 diabetes. FierceBiotech News

Onslaught of new drugs will shake up MS, diabetes, cancer and more

Tracy Staton A bumper crop of FDA approvals in 2015 means an equal number of launches to keep an eye on in 2016. Last year, FiercePharmaMarketing brought you a list of 8 markets to ...

Startup raises $15M to turn an old diabetes drug into a potent cancer killer

Damian Garde A group of scientists at UCLA have cooked up some compounds that could harness the cancer-fighting properties of metformin while avoiding the biological hurdles that have ...

FDA rejects AstraZeneca’s diabetes combo and demands more data

Damian Garde The FDA wants to see more clinical trial data on AstraZeneca's new combination diabetes treatment, the company said, likely delaying a potential launch by more than ...

Novo Nordisk launches diabetes ‘dream team’ contest with NBA star as a prize

Carly Helfand Former NBA star Dominique Wilkins is not just a spokesman for Novo Nordisk's Victoza. He's also a prize in a Type 2 diabetes sweepstakes the drugmaker is rolling ...

Novo heralds promising PhIII diabetes data for once-weekly semaglutide

John Carroll Novo Nordisk is touting the first Phase III success for its once-weekly GLP-1 therapy semaglutide. The Danish pharma company says that two doses of the drug–a key ...

Novo Nordisk backs out of a diabetes deal with Zosano

Damian Garde Novo Nordisk has terminated a collaboration deal with Zosano Pharma, walking away from an agreement that would have paired its late-stage diabetes drug with the latter ...

Are CV studies worth it for diabetes meds? After Merck and Sanofi’s recent successes, some say no

Carly Helfand Some industry watchers are wondering whether those large, expensive trials–which aren't long enough to establish long-term outcomes–were worth it. FiercePharma ...

Pharma hikes prices on all sorts of meds, but hit diabetes hardest: Bloomberg

Tracy Staton Twenty-seven drug brands took 20% price increases last year, and dozens saw prices at least double over the past 5 years, Bloomberg reports. Once again, the usual suspects ...

Safety scare with AstraZeneca’s diabetes drug could shake up the DPP-4 field

Damian Garde The FDA raised some alarming concerns tied to AstraZeneca's Onglyza ahead of a committee meeting to discuss the safety of so-called DPP-4 inhibitors, sounding a worrying ...

Lilly and Boehringer roll toward EU approval with diabetes combo

Damian Garde Eli Lilly and Boehringer Ingelheim secured a recommendation from European regulators for their combination diabetes treatment, making for a likely continental approval ...
Page 1 of 812345...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS